Depressive symptoms in first episode schizophrenia patients under treatment: one-year follow-up comparison of classical and atypical antipsychotics

2015 ◽  
Vol 16 (1) ◽  
pp. 7
Author(s):  
Tunay Karlidere ◽  
Ozcan Uzun ◽  
Adem Balikci
2009 ◽  
Vol 33 (8) ◽  
pp. 1438-1446 ◽  
Author(s):  
Tomas Kasparek ◽  
Radovan Prikryl ◽  
Daniel Schwarz ◽  
Hana Kucerova ◽  
Radek Marecek ◽  
...  

1988 ◽  
Vol 152 (4) ◽  
pp. 470-476 ◽  
Author(s):  
Robin G. McCreadie ◽  
David H. Wiles ◽  
Stewart M. Grant ◽  
John W. Moore ◽  
George T. Crocket ◽  
...  

Of 49 schizophrenic patients followed up 12 months after their first admission to hospital, only about 45% had experienced no relapse and had no schizophrenic symptoms; a poorer outcome was more often found in Feighner positive than Feighner negative schizophrenic patients. The patients' overall level of unemployment had more than doubled to 51%. In patients whose acute episodes responded to treatment, pimozide taken once weekly as maintenance therapy was as effective as intramuscular flupenthixol decanoate, but tardive dyskinesia appeared in two patients receiving weekly pimozide; the repeat psychometric assessment at 12 months found modest improvements, i.e. no evidence of intellectual decline, in Matrices, Block Design, and Digit Copying tests. Forty per cent of relatives still showed significant psychological distress, which correlated with patients' schizophrenic symptoms, and the relatives' social functioning remained poorer than that of a normal community sample.


2007 ◽  
Vol 38 (1) ◽  
pp. 79-88 ◽  
Author(s):  
I. Harrison ◽  
E. M. Joyce ◽  
S. H. Mutsatsa ◽  
S. B. Hutton ◽  
V. Huddy ◽  
...  

BackgroundThe impact of co-morbid substance use in first-episode schizophrenia has not been fully explored.MethodThis naturalistic follow-up of a cohort of 152 people with first-episode schizophrenia examined substance use and clinical outcome in terms of symptoms and social and neuropsychological function.ResultsData were collected on 85 (56%) of the patient cohort after a median period of 14 months. Over the follow-up period, the proportion of smokers rose from 60% at baseline to 64%. While 30% reported lifetime problem drinking of alcohol at baseline, only 15% had problem drinking at follow-up. Furthermore, while at baseline 63% reported lifetime cannabis use and 32% were currently using the drug, by the follow-up assessment the latter figure had fallen to 18.5%. At follow-up, persistent substance users had significantly more severe positive and depressive symptoms and greater overall severity of illness. A report of no lifetime substance use at baseline was associated with greater improvement in spatial working memory (SWM) at follow-up.ConclusionsPast substance use may impede recovery of SWM performance in people with schizophrenia in the year or so following first presentation to psychiatric services. The prevalence of substance use other than tobacco tends to diminish over this period, in the absence of specific interventions. Persistent substance use in first-episode schizophrenia is associated with more severe positive and depressive symptoms but not negative symptoms, and should be a target for specific treatment intervention.


2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Nasrettin Sönmez ◽  
Kristin Lie Romm ◽  
Ole A Andreasssen ◽  
Ingrid Melle ◽  
Jan Ivar Røssberg

2012 ◽  
Vol 54 (3) ◽  
pp. 248 ◽  
Author(s):  
Amresh Shrivastava ◽  
Kristen Terpstra ◽  
Larry Stitt ◽  
Nilesh Shah ◽  
Megan Johnston

2014 ◽  
Vol 159 (2-3) ◽  
pp. 465-470 ◽  
Author(s):  
Jia-Qi Xu ◽  
Christy Lai-Ming Hui ◽  
Julia Longenecker ◽  
Edwin Ho-Ming Lee ◽  
Wing-Chung Chang ◽  
...  

2002 ◽  
Vol 58 (2-3) ◽  
pp. 247-252 ◽  
Author(s):  
P OOSTHUIZEN ◽  
R EMSLEY ◽  
M ROBERTS ◽  
J TURNER ◽  
L KEYTER ◽  
...  

1987 ◽  
Vol 151 (6) ◽  
pp. 773-779 ◽  
Author(s):  
Allan House ◽  
Janet Bostock ◽  
John Cooper

A complete, unselected series of 68 patients who were seen during their first episode of an undoubtedly schizophrenic illness, and followed up one year later (for 56 patients) is described clinically. Depressive symptoms were common at onset, and 22% of patients could have been considered cases of depression from these symptoms alone. At follow-up, depressive symptoms had reduced in prevalence and only 7% of subjects were depressed cases. Only two cases of depression at follow-up had not been cases at onset. These changes could not be attributed to the use of antidepressants or ECT. Depressive syndromes could be distinguished from akinesia and the negative syndromes. The findings indicate that depression cannot be attributed solely to the administration of neuroleptics.


Sign in / Sign up

Export Citation Format

Share Document